Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2013-07-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00432-013-1476-3PMID 23892407PMCID PMC11824581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NF‐κB and the link between inflammation and cancer

  2012cited by this paper
• Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF‐κB via targeting of Mre11

  2012cited by this paper
• Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-β1 up-regulation in proximal tubular epithelial cells.

  2012cited by this paper
• In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

  2010cited by this paper
• cIAP2 as a therapeutic target in colorectal cancer and other malignancies

  2009cited by this paper
• Temporal trends in breast cancer mortality by state and race

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival

  2008cited by this paper
• Active roles for inhibitory κB kinases α and β in nuclear factor-κB–mediated chemoresistance to doxorubicin

  2008cited by this paper
• Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression

  2006cited by this paper
• Nuclear factor-kappaB in cancer development and progression.

  2006cited by this paper
• PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress

  2006cited by this paper
• NF-kappaB and IKK as therapeutic targets in cancer.

  2006cited by this paper
• NF-κB and IKK as therapeutic targets in cancer

  2006cited by this paper
• Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.

  2006cited by this paper
• Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway

  2006cited by this paper
• Nuclear factor-κB in cancer development and progression

  2006cited by this paper
• Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.

  2006cited by this paper
• PIDD Mediates NF-k BA ctivation in Response to DNA Damage

  2005cited by this paper
• The NF-κB/IκB signaling system: A molecular target in breast cancer therapy

  2005cited by this paper
• The NF-kappaB pathway.

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy.

  2005cited by this paper
• PIDD mediates NF-kappaB activation in response to DNA damage.

  2005cited by this paper
• The NF-κB pathway

  2005cited by this paper
• NF-κB: linking inflammation and immunity to cancer development and progression

  2005cited by this paper
• NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis

  2004cited by this paper
• Signaling to NF-kappaB.

  2004cited by this paper
• NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.

  2004cited by this paper
• IκB Kinase-Independent IκBα Degradation Pathway: Functional NF-κB Activity and Implications for Cancer Therapy

  2003cited by this paper
• Nuclear transcription factor-κB as a target for cancer drug development

  2002cited by this paper
• Nuclear transcription factor-kappaB as a target for cancer drug development.

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• NF-κB in cancer: from innocent bystander to major culprit

  2002cited by this paper
• NF-kappaB at the crossroads of life and death.

  2002cited by this paper
• NF-κB at the crossroads of life and death

  2002cited by this paper
• Inactivation of NF-κB-Dependent Cell Survival, a Novel Mechanism for the Proapoptotic Function of c-Abl

  2002cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

  2001cited by this paper
• Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activation

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

  2001cited by this paper
• Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3

  2000cited by this paper
• Crucial Role of the Amino-Terminal Tyrosine Residue 42 and the Carboxyl-Terminal PEST Domain of IκBα in NF-κB Activation by an Oxidative Stress1

  2000cited by this paper
• Pervanadate-induced Nuclear Factor-κB Activation Requires Tyrosine Phosphorylation and Degradation of IκBα

  2000cited by this paper
• Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha.

  2000cited by this paper
• Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.

  2000cited by this paper
• Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.

  2000cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper
• Activators and target genes of Rel/NF-κB transcription factors

  1999cited by this paper
• Activators and target genes of Rel/NF-kappaB transcription factors.

  1999cited by this paper
• Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

  1997cited by this paper
• Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth

  1997cited by this paper
• Site-specific tyrosine phosphorylation of IkappaBalpha negatively regulates its inducible phosphorylation and degradation.

  1996cited by this paper
• Site-specific Tyrosine Phosphorylation of IκBα Negatively Regulates Its Inducible Phosphorylation and Degradation*

  1996cited by this paper
• Tyrosine Phosphorylation of I?B-a Activates NF-?B without Proteolytic Degradation of I?B-a

  1996cited by this paper
• Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha.

  1996cited by this paper

• Emerging Targets and Treatments for Doxorubicin-Induced Cardiac Inflammation.

  2026cites this paper
• c-Abl Phosphorylates Plk1 in Facilitating DNA Damage-Induced G2/M Checkpoint Release with a Trade-off of Micronuclei Formation

  2025cites this paper
• The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes

  2024cites this paper
• A comprehensive review of cellular stress response pathway system of Rhizoma coptidis

  2024cites this paper
• Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity

  2024cites this paper
• Triple Reporter Assay: A Non-Overlapping Luciferase Assay for the Measurement of Complex Macromolecular Regulation in Cancer Cells Using a New Mushroom Luciferase–Luciferin Pair

  2023cites this paper
• IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer

  2022cites this paper
• Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer

  2022cites this paper
• α-Mangostin Synergizes the Antineoplastic Effects of 5-Fluorouracil Allowing a Significant Dose Reduction in Breast Cancer Cells

  2021cites this paper
• Up-Regulation of Fibroblast Growth Factor 23 Gene Expression in UMR106 Osteoblast-like Cells with Reduced Viability

  2021cites this paper
• Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro.

  2021cites this paper
• HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology.

  2020cites this paper
• Antimicrobial Peptide against Mycobacterium Tuberculosis That Activates Autophagy Is an Effective Treatment for Tuberculosis

  2020cites this paper
• FASN Negatively Regulates NF-kB/P65 Expression in Breast Cancer Cells by Disrupting Its Stability

  2020cites this paper
• Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

  2020cites this paper
• Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways

  2019cites this paper
• Insights into the transcriptional regulation of the anthracycline reductase AKR7A2 in human cardiomyocytes.

  2019cites this paper
• A Practical Review of Proteasome Pharmacology

  2019cites this paper
• Activation of NF-κB in B cell receptor signaling through Bruton’s tyrosine kinase-dependent phosphorylation of IκB-α

  2019cites this paper
• Synergistic Antitumorigenic Activity of Calcitriol with Curcumin or Resveratrol is Mediated by Angiogenesis Inhibition in Triple Negative Breast Cancer Xenografts

  2019cites this paper
• Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways

  2018cites this paper
• Ginger extract adjuvant to doxorubicin in mammary carcinoma: study of some molecular mechanisms

  2018cites this paper
• Cellular stress response mechanisms of Rhizoma coptidis: a systematic review

  2018influential citation
• Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.

  2018cites this paper
• Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System

  2017cites this paper
• Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic Kinases

  2017cites this paper
• Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities.

  2017cites this paper
• NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization.

  2016cites this paper
• Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production.

  2016cites this paper
• Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment

  2016cites this paper
• Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases

  2016influential citation
• Calcitriol stimulates gene expression of cathelicidin antimicrobial peptide in breast cancer cells with different phenotype

  2016influential citation
• Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells

  2016influential citation
• Multifunctional Abl kinases in health and disease

  2016cites this paper
• Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.

  2015cites this paper
• In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors

  2014cites this paper
• Targeting the NFκB signaling pathways for breast cancer prevention and therapy.

  2014cites this paper